Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review

A systemic review of 50 studies found that aromatase inhibitor–induced musculoskeletal signs and symptoms (AIMSS) involve intersecting hormonal, genetic, inflammatory, and neural pathways. Identifying biomarkers may support risk stratification and targeted interventions, although further research is needed to validate this and to tailor interventions.